Mind Medicine (MNMD)

Overall impact
B (76)

Commentary

Mind Medicine is a strong overall performer. With a 'B' rating of 75.8 for overall impact (90th percentile compared to all companies), Mind Medicine ranks 127th out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 123 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 455 others. On top material causes for Mind Medicine's industry (Pharmaceuticals & Biotech), Mind Medicine performs well in Child and Maternal Health (95.0 score), Sustainable Use of Water (95.1), Child and Maternal Health (96.2) and 8 other causes where it received an 'A' score and performs poorly in Decent, Safe Work Opportunities (38.2 score), Disaster Readiness and Effective Aid (28.0), Reduced Green House Gas Emissions (24.4) and 1 other cause where it received a 'D' or 'F' score.
Impact
Cause MNMD
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2019
Employees
74
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ny, United States
Share classes
MNMD
Description
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
Material causes
Ethos considers the following causes material for Mind Medicine, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.